MetroPCS Communications, Inc. (NYSE:PCS): Deutsche Bank believes that the possible merger between MetroPCS and T-Mobile USA could be the first step in becoming more competitive. The firm increased its Buy rating and price target on the stock.
Medivation, Inc. (NASDAQ:MDVN): According to Citigroup, it continues to be positive regarding Medivation shares although there is strong appreciation in the stock. The firm thinks that Xtandi has had a a solid launch in the U.S. and that the pre-chemo market could be larger than expected. Citi has increased Buy rating and its price target to $70 on the stock.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Netflix, Inc. (NASDAQ:NFLX): Citigroup stated that its most recent proprietary consumer survey showed improvement in satisfaction with Netflix first time since last summer. Citi believes that the current valuation is reasonable for Netflix shares, and it keeps its Buy rating and a $120 price target on the stock.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Jefferies predicts that there will be a 60 to 85 percent probability to succeed for BioMarin’s GALNS Phase 3 data for Morquio A syndrome, and it sees a 25 to 30 percent possible upside from current share levels on positive results. The firm keeps a Buy rating and increases its price target to $46 from $44 on the stock.
Yahoo! Inc. (NASDAQ:YHOO): According to Piper Jaffray, its channel checks suggest 89 percent of Yahoo!’s homepage inventory was sold on a guaranteed basis, compared to 65 percent last September and 43 percent during August. Piper believes that this monthly improvement is an indication that Yahoo!’s core business could see a turnaround. The firm keeps its Neutral rating and $18 price target on the stock.
Don’t Miss: Amazon is Making Enemies.